These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

968 related articles for article (PubMed ID: 24334603)

  • 21. A novel small molecule RAD51 inactivator overcomes imatinib-resistance in chronic myeloid leukaemia.
    Zhu J; Zhou L; Wu G; Konig H; Lin X; Li G; Qiu XL; Chen CF; Hu CM; Goldblatt E; Bhatia R; Chamberlin AR; Chen PL; Lee WH
    EMBO Mol Med; 2013 Mar; 5(3):353-65. PubMed ID: 23341130
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CD-200 induces apoptosis and inhibits Bcr-Abl signaling in imatinib-resistant chronic myeloid leukemia with T315I mutation.
    Fang Z; Jung KH; Yan HH; Kim SJ; Son MK; Rumman M; Lee H; Kim KW; Yoo HD; Hong SS
    Int J Oncol; 2015 Jul; 47(1):253-61. PubMed ID: 25963192
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aberrant signalling by protein kinase CK2 in imatinib-resistant chronic myeloid leukaemia cells: biochemical evidence and therapeutic perspectives.
    Borgo C; Cesaro L; Salizzato V; Ruzzene M; Massimino ML; Pinna LA; Donella-Deana A
    Mol Oncol; 2013 Dec; 7(6):1103-15. PubMed ID: 24012109
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preclinical development of a novel BCR-ABL T315I inhibitor against chronic myeloid leukemia.
    Gupta P; Zhang GN; Barbuti AM; Zhang X; Karadkhelkar N; Zhou J; Ding K; Pan J; Yoganathan S; Yang DH; Chen ZS
    Cancer Lett; 2020 Mar; 472():132-141. PubMed ID: 31837444
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design, synthesis, and biological evaluation of novel water-soluble triptolide derivatives: Antineoplastic activity against imatinib-resistant CML cells bearing T315I mutant Bcr-Abl.
    Xu F; Shi X; Li S; Cui J; Lu Z; Jin Y; Lin Y; Pang J; Pan J
    Bioorg Med Chem; 2010 Mar; 18(5):1806-15. PubMed ID: 20149665
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanism.
    Zhang H; Trachootham D; Lu W; Carew J; Giles FJ; Keating MJ; Arlinghaus RB; Huang P
    Leukemia; 2008 Jun; 22(6):1191-9. PubMed ID: 18385754
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells.
    Bartholomeusz GA; Talpaz M; Kapuria V; Kong LY; Wang S; Estrov Z; Priebe W; Wu J; Donato NJ
    Blood; 2007 Apr; 109(8):3470-8. PubMed ID: 17202319
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Piperlongumine overcomes imatinib resistance by inducing proteasome inhibition in chronic myelogenous leukemia cells.
    Lan X; Hu M; Jiang L; Wang J; Meng Y; Chen X; Liu A; Ding W; Zhang H; Zhou H; Liu B; Peng G; Liao S; Chen X; Liu J; Shi X
    J Ethnopharmacol; 2023 Jan; 301():115815. PubMed ID: 36220508
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low-level expression of proapoptotic Bcl-2-interacting mediator in leukemic cells in patients with chronic myeloid leukemia: role of BCR/ABL, characterization of underlying signaling pathways, and reexpression by novel pharmacologic compounds.
    Aichberger KJ; Mayerhofer M; Krauth MT; Vales A; Kondo R; Derdak S; Pickl WF; Selzer E; Deininger M; Druker BJ; Sillaber C; Esterbauer H; Valent P
    Cancer Res; 2005 Oct; 65(20):9436-44. PubMed ID: 16230407
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
    Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
    Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Proliferation inhibition and apoptosis induction of imatinib-resistant chronic myeloid leukemia cells via PPP2R5C down-regulation.
    Shen Q; Liu S; Chen Y; Yang L; Chen S; Wu X; Li B; Lu Y; Zhu K; Li Y
    J Hematol Oncol; 2013 Sep; 6():64. PubMed ID: 24004697
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Proteasome inhibition causes regression of leukemia and abrogates BCR-ABL-induced evasion of apoptosis in part through regulation of forkhead tumor suppressors.
    Jagani Z; Song K; Kutok JL; Dewar MR; Melet A; Santos T; Grassian A; Ghaffari S; Wu C; Yeckes-Rodin H; Ren R; Miller K; Khosravi-Far R
    Cancer Res; 2009 Aug; 69(16):6546-55. PubMed ID: 19654305
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides.
    Aichberger KJ; Mayerhofer M; Krauth MT; Skvara H; Florian S; Sonneck K; Akgul C; Derdak S; Pickl WF; Wacheck V; Selzer E; Monia BP; Moriggl R; Valent P; Sillaber C
    Blood; 2005 Apr; 105(8):3303-11. PubMed ID: 15626746
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alantolactone induces apoptosis in chronic myelogenous leukemia sensitive or resistant to imatinib through NF-κB inhibition and Bcr/Abl protein deletion.
    Wei W; Huang H; Zhao S; Liu W; Liu CX; Chen L; Li JM; Wu YL; Yan H
    Apoptosis; 2013 Sep; 18(9):1060-70. PubMed ID: 23613107
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Overcoming CML acquired resistance by specific inhibition of Aurora A kinase in the KCL-22 cell model.
    Yuan H; Wang Z; Zhang H; Roth M; Bhatia R; Chen WY
    Carcinogenesis; 2012 Feb; 33(2):285-93. PubMed ID: 22116466
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aurora A Kinase Inhibitor AKI603 Induces Cellular Senescence in Chronic Myeloid Leukemia Cells Harboring T315I Mutation.
    Wang LX; Wang JD; Chen JJ; Long B; Liu LL; Tu XX; Luo Y; Hu Y; Lin DJ; Lu G; Long ZJ; Liu Q
    Sci Rep; 2016 Nov; 6():35533. PubMed ID: 27824120
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutation.
    Okabe S; Tauchi T; Tanaka Y; Kitahara T; Kimura S; Maekawa T; Ohyashiki K
    Cancer Biol Ther; 2014 Feb; 15(2):207-15. PubMed ID: 24100660
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Silencing of suppressor of cytokine signaling-3 due to methylation results in phosphorylation of STAT3 in imatinib resistant BCR-ABL positive chronic myeloid leukemia cells.
    Al-Jamal HA; Jusoh SA; Yong AC; Asan JM; Hassan R; Johan MF
    Asian Pac J Cancer Prev; 2014; 15(11):4555-61. PubMed ID: 24969884
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterization of imatinib-resistant K562 cell line displaying resistance mechanisms.
    Hekmatshoar Y; Ozkan T; Altinok Gunes B; Bozkurt S; Karadag A; Karabay AZ; Sunguroglu A
    Cell Mol Biol (Noisy-le-grand); 2018 May; 64(6):23-30. PubMed ID: 29808796
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Induction of autophagy by Imatinib sequesters Bcr-Abl in autophagosomes and down-regulates Bcr-Abl protein.
    Elzinga BM; Nyhan MJ; Crowley LC; O'Donovan TR; Cahill MR; McKenna SL
    Am J Hematol; 2013 Jun; 88(6):455-62. PubMed ID: 23440701
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 49.